Addex Therapeutics has issued 93 million new registered shares, increasing its issued share capital to CHF 3,116,544.96 with 311,654,496 shares at a nominal value of CHF 0.01 each. These shares were fully subscribed by its wholly-owned subsidiary, Addex Pharma S.A, and are listed on the SIX Swiss Exchange. This move is intended to provide Addex with greater flexibility for future financing as it continues developing novel treatments for neurological disorders. The number of outstanding shares remains unchanged despite the increase in issued share capital.
Addex Therapeutics' recent increase in issued share capital provides context for readers. For those following the health sector, here is Pluang's market snapshot as of Oct 29, 2026 10:11 WIB: out of 150 priced health-sector US stocks, 107 rose and 42 fell. Notable movers include INO (Inovio Pharmaceuticals Inc) at USD 0.97 with a 1-day change of +8.99% and Pluang order activity of 65% Sell / 35% Buy, CLPT (ClearPoint Neuro Inc) at USD 10.50 with a 1-day change of +8.36% and balanced order activity, and GEHC (GE HealthCare Technologies Inc. Common Stock) at USD 76.27 with a 1-day change of +7.26%.
TGS ASA announced that its shares will be traded ex-dividend at NOK 1.45 per share starting October 29, 2026. This means investors buying the stock from this date will not receive the upcoming dividend payment. The dividend distribution follows appro...
DNO ASA, a Norwegian oil and gas company, announced a cash dividend of NOK 0.375 per share to be paid around November 17, 2026. Shareholders registered by November 9, 2026, will receive the dividend, with shares trading ex-dividend starting November ...
The global music market is projected to grow from $36.13 billion in 2026 to $57.74 billion by 2032, at a CAGR of 8.07%, fueled by paid streaming subscriptions, smartphone adoption, and digital music discovery. North America remains the largest market...
STMicroelectronics reported a 17.9% year-over-year increase in Q3 2026 net revenues to $3.76 billion and net income of $291 million, driven by growth in consumer electronics and personal electronics segments. Gross margin improved to 37.3%, and opera...
Molecular Partners reported Q3 2026 results highlighting a strategic shift to radiopharmaceuticals, driven by encouraging Phase 1/2a data from its lead candidate MP0712 for small cell lung cancer. The company is streamlining operations, planning to c...
